Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

LENZ Therapeutics (LENZ) Enterprise Value (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Enterprise Value for 4 consecutive years, with -$292.3 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value fell 39.86% to -$292.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$292.3 million through Dec 2025, down 39.86% year-over-year, with the annual reading at -$292.3 million for FY2025, 39.86% down from the prior year.
  • Enterprise Value for Q4 2025 was -$292.3 million at LENZ Therapeutics, down from -$25.4 million in the prior quarter.
  • The five-year high for Enterprise Value was -$23.2 million in Q1 2025, with the low at -$339.2 million in Q1 2022.
  • Average Enterprise Value over 4 years is -$195.3 million, with a median of -$209.0 million recorded in 2024.
  • Peak annual rise in Enterprise Value hit 88.45% in 2025, while the deepest fall reached 39.86% in 2025.
  • Over 4 years, Enterprise Value stood at -$268.2 million in 2022, then rose by 12.77% to -$234.0 million in 2023, then grew by 10.67% to -$209.0 million in 2024, then plummeted by 39.86% to -$292.3 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$292.3 million, -$25.4 million, and -$37.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.